Document:

EX-4.4

 Exhibit 4.4 

WARRANT AGREEMENT 
 This
WARRANT AGREEMENT (this “Agreement”) is made as of                     , 2021 between OPY Acquisition Corp. I, a
Delaware corporation, with offices at 85 Broad Street, New York, New York, 10004 (“Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, with offices at 1 State Street, New
York, New York 10004, as warrant agent (“Warrant Agent”). 
 WHEREAS, the Company is engaged in a public offering
(“Public Offering”) of up to 11,500,000 units (including 1,500,000 units which may be issued pursuant to an overallotment option granted to the underwriters of the Public Offering), each unit (the “Public Units”)
comprised of one share of the common stock, par value $.0001 per share (“Common Stock”), and one-third of one warrant, where each whole warrant entitles the holder to purchase one share of
Common Stock at a price of $11.50 per share, subject to adjustment as described herein, and, in connection therewith, will issue and deliver up to 3,833,334 warrants (the “Public Warrants”) to the public investors in connection with
the Public Offering; and 
 WHEREAS, in lieu of cash compensation, the Company has agreed to compensate the underwriter in the Public
Offering with up to 1,533,333 warrants (the “Underwriter Warrants”); 
 WHEREAS, the Company has filed with the Securities and
Exchange Commission (the “SEC”) a Registration Statement on Form S-1,
No. 333-             (“Registration Statement”) and prospectus (“Prospectus”), for the registration,
under the Securities Act of 1933, as amended (“Act”) of, among other securities, the Public Warrants and the Underwriter Warrants; and 

WHEREAS, the Company has received binding commitments (“Subscription Agreements”) from the Company’s sponsor, OPY
Acquisition LLC I to purchase, simultaneously with the closing of the Public Offering, 1,367,333 warrants (the “Private Warrants”), each exercisable to purchase one share of Common Stock at a price of $11.50 per share, bearing the
legend set forth in Exhibit B hereto; and 
 WHEREAS, the Company may issue up to an additional 1,333,333 warrants (the “Working
Capital Warrants”) at a price of $1.50 per Working Capital Warrant, in satisfaction of certain working capital loans made by the Company’s officers, directors, initial stockholders and their affiliates; and 

WHEREAS, following consummation of the Public Offering, the Company may issue additional warrants (“Post IPO Warrants” and
together with the Public Warrants, Underwriter Warrants, Private Warrants, and Working Capital Warrants, the “Warrants”) in connection with, or following the consummation by the Company of, a Business Combination (defined below);
and 
 WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in
connection with the issuance, registration, transfer, exchange, redemption, and exercise of the Warrants; and 
 WHEREAS, the Company
desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the
Warrants; and 
 WHEREAS, all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf
of the Company and countersigned by or on behalf of the Warrant Agent, as provided herein, the valid, binding, and legal obligations of the Company, and to authorize the execution and delivery of this Agreement. 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows: 

1. Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant
Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement. 

  
 1 

 2. Warrants. 

2.1. Form of Warrant. Each Warrant shall be issued in registered form only, shall be in substantially the form of Exhibit A hereto,
the provisions of which are incorporated herein and shall be signed by, or bear the facsimile signature of, the Chairman of the Board of Directors or Chief Executive Officer and Treasurer, Secretary or Assistant Secretary of the Company and shall
bear a facsimile of the Company’s seal. In the event the person whose facsimile signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may
be issued with the same effect as if he or she had not ceased to be such at the date of issuance. 
 2.2. Uncertificated
Warrants. Notwithstanding anything herein to the contrary, any Warrant, or portion thereof, may be issued as part of, and be represented by, a Unit, and any Warrant may be issued in uncertificated or book-entry form through the Warrant Agent
and/or the facilities of The Depository Trust Company (the “Depositary”) or other book-entry depositary system, in each case as determined by the Board of Directors of the Company or by an authorized committee thereof. Any Warrant
so issued shall have the same terms, force and effect as a certificated Warrant that has been duly countersigned by the Warrant Agent in accordance with the terms of this Agreement. 

2.3. Effect of Countersignature. Except with respect to uncertificated Warrants as described above, unless and until countersigned
by the Warrant Agent pursuant to this Agreement, a Warrant shall be invalid and of no effect and may not be exercised by the holder thereof. 

2.4. Registration. 

2.4.1. Warrant Register. The Warrant Agent shall maintain books (“Warrant Register”) for the registration of
original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise
in accordance with instructions delivered to the Warrant Agent by the Company. 
 2.4.2. Registered Holder. Prior to due
presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat the person in whose name such Warrant is then registered in the Warrant Register (“registered holder”) as the absolute
owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing on the Warrant certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise
thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. 

2.5. Detachability of Warrants. The securities comprising the Units will not be separately transferable until the 52nd day following the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday, Sunday or federal holiday, on which banks
in New York City are generally open for normal business (a “Business Day”), then on the immediately succeeding Business Day following such date, or earlier with the consent of Oppenheimer & Co. Inc. (the
“Representative”), but in no event will the Representative allow separate trading of the securities comprising the Units until (i) the Company has filed a Current Report on
Form 8-K which includes an audited balance sheet reflecting the receipt by the Company of the gross proceeds of the Public Offering including the proceeds received by the Company from the exercise of
the underwriters’ over-allotment option in the Public Offering, if the over-allotment option is exercised prior to the filing of the Form 8-K, and (ii) the Company has issued a press
release and has filed a Current Report on Form 8-K announcing when such separate trading shall begin (the “Detachment Date”). 

2.6. Private Warrant and Working Capital Warrant and Underwriter Warrant Attributes. The Private Warrants, Working Capital
Warrants and Underwriter Warrants will be identical to the Public Warrants. 
 2.7. Post IPO Warrants. The Post IPO Warrants,
when and if issued, shall have the same terms and be in the same form as the Public Warrants except as may be agreed upon by the Company. 

  
 2 

 3. Terms and Exercise of Warrants 

3.1. Warrant Price. Each Warrant shall, when countersigned by the Warrant Agent (except with respect to uncertificated Warrants),
entitle the registered holder thereof, subject to the provisions of such Warrant and of this Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the price of $11.50 per share, subject to the adjustments
provided in Section 4 hereof and in the last sentence of this Section 3.1. The term “Warrant Price” as used in this Agreement refers to the price per share at which the Common Stock may be purchased at the time a Warrant is
exercised. The Company in its sole discretion may lower the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) Business Days; provided, that the Company shall provide at least
twenty (20) days’ prior written notice of such reduction to registered holders of the Warrants and, provided further that any such reduction shall be applied consistently to all of the Warrants. 

3.2. Duration of Warrants. A Warrant may be exercised only during the period commencing 30 days after the consummation by the
Company of a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (“Business Combination”) (as described more fully
in the Registration Statement), and terminating at 5:00 p.m., New York City time on the earlier to occur of (i) the date that is five (5) years after the date on which the Company consummates a Business Combination, (ii) at 5:00 p.m.,
New York City time on the Redemption Date as provided in Section 6.2 of this Agreement and (iii) the liquidation of the Trust Account (defined below) (“Expiration Date”). The period of time from the date the Warrants
will first become exercisable until the expiration of the Warrants shall hereafter be referred to as the “Exercise Period.” Except with respect to the right to receive the Redemption Price (as set forth in Section 6 hereunder), as
applicable, each outstanding Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at the close of business on the Expiration Date. The
Company in its sole discretion may extend the duration of the Warrants by delaying the Expiration Date; provided, however, that the Company will provide at least twenty (20) days’ prior written notice of any such extension to registered
holders and, provided further that any such extension shall be applied consistently to all of the Warrants. 
 3.3. Exercise of
Warrants. 
 3.3.1. Payment. Subject to the provisions of the Warrant and this Agreement, a Warrant, when countersigned by
the Warrant Agent, may be exercised by the registered holder thereof by surrendering it, at the office of the Warrant Agent, or at the office of its successor as Warrant Agent, in the Borough of Manhattan, City and State of New York, with the
subscription form, as set forth in the Warrant, duly executed, and by paying in full the Warrant Price for each share of Common Stock as to which the Warrant is exercised and any and all applicable taxes due in connection with the exercise of the
Warrant, as follows: 
 (a) in lawful money of the United States, by good certified check or good bank draft payable to the
order of the Warrant Agent or wire transfer; 
 (b) in the event of a redemption pursuant to Section 6.1 hereof in which
the Company’s management has elected to force all holders of Warrants to exercise such Warrants on a “cashless basis,” by surrendering the Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing
(x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the difference between the Warrant Price and the “Fair Market Value” (defined below) by (y) the Fair Market Value. Solely for purposes
of this Section 3.3.1(b), the “Fair Market Value” shall mean the average reported closing price of the Common Stock for the ten (10) trading days ending on the third trading day prior to the date on which the notice of redemption
is sent to holders of the Warrants pursuant to Section 6 hereof; or 
 (c) in the event the registration statement
required by Section 7.4 hereof is not effective and current within sixty (60) days after the closing of a Business Combination, by surrendering such Warrants for that number of shares of Common Stock equal to the quotient obtained by
dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the difference between the exercise price of the Warrants and the “Fair Market Value” by (y) the Fair Market Value; provided,
however, that no cashless exercise shall be permitted unless the Fair Market Value is equal to or higher than the exercise price. Solely for purposes of this Section 3.3.1(c), the “Fair Market Value” shall mean the average reported
last sale price of the Common Stock for the ten (10) trading days ending on the trading day prior to the date of exercise. 

  
 3 

 3.3.2. Issuance of Common Stock. As soon as practicable after the exercise of
any Warrant and the clearance of the funds in payment of the Warrant Price (if any), the Company shall issue to the registered holder of such Warrant a certificate or certificates, or book entry position, for the number of shares of Common Stock to
which he, she or it is entitled, registered in such name or names as may be directed by him, her or it, and if such Warrant shall not have been exercised in full, a new countersigned Warrant, or book entry position, for the number of shares as to
which such Warrant shall not have been exercised. Notwithstanding the foregoing, in no event will the Company be required to net cash settle the Warrant exercise. No Warrant shall be exercisable for cash and the Company shall not be obligated to
issue Common Stock upon exercise of a Warrant unless the Common Stock issuable upon such Warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the
Warrants. In the event that the condition in the immediately preceding sentence is not satisfied with respect to a Warrant, the holder of such Warrant shall not be entitled to exercise such Warrant for cash and such Warrant may have no value and
expire worthless, in which case the purchaser of a Unit containing such Warrants shall have paid the full purchase price for the Unit solely for the Common Stock underlying such Unit. Warrants may not be exercised by, or securities issued to, any
registered holder in any state in which such exercise or issuance would be unlawful. 
 3.3.3. Valid Issuance. All Common Stock
issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly issued, fully paid and nonassessable. 

3.3.4. Date of Issuance. Each person in whose name any book entry position or certificate for Common Stock is issued shall for all
purposes be deemed to have become the holder of record of such shares on the date on which the Warrant, or book entry position representing such Warrant, was surrendered and payment of the Warrant Price was made, irrespective of the date of delivery
of such certificate, except that, if the date of such surrender and payment is a date when the share transfer books of the Company or book entry system of the Warrant Agent are closed, such person shall be deemed to have become the holder of such
shares at the close of business on the next succeeding date on which the share transfer books or book entry system are open. 

3.3.5 Maximum Percentage. A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the
provisions contained in this subsection 3.3.5; however, no holder of a Warrant shall be subject to this subsection 3.3.5 unless he, she or it makes such election. If the election is made by a holder, the Warrant Agent shall not cause the exercise of
the holder’s Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the Warrant Agent’s actual
knowledge, would beneficially own in excess of 4.99 or 9.99% (the “Maximum Percentage”) of the Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number
of shares of Common Stock beneficially owned by such person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made, but shall
exclude shares of Common Stock that would be issuable upon (x) exercise of the remaining, unexercised portion of the Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or
unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion
or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”). For purposes of the Warrant, in determining the number of outstanding shares of Common Stock, the holder may rely on the number of outstanding shares of Common Stock as reflected in
(1) the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, current report on
Form 8-K or other public filing with the SEC as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Warrant Agent setting
forth the number of shares of Common Stock outstanding. For any reason at any time, upon the written request of the holder of the Warrant, the Company shall, within two (2) Business Days, confirm orally and in writing to such holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of equity securities of the Company by the holder and its affiliates
since the date as of which such number of outstanding shares of Common 

  
 4 

 
Stock was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum Percentage applicable to such holder to any other percentage
specified in such notice; provided, however, that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company. 

4. Adjustments. 
 4.1. Stock
Dividends; Split Ups. If after the date hereof, and subject to the provisions of Section 4.6 below, the number of outstanding shares of Common Stock is increased by a stock dividend payable in Common Stock, or by a split up of Common Stock,
or other similar event, then, on the effective date of such stock dividend, split up or similar event, the number of shares of Common Stock issuable on exercise of each Warrant shall be increased in proportion to such increase in outstanding shares
of Common Stock. 
 4.2. Aggregation of Shares. If after the date hereof, the number of outstanding shares of Common Stock is
decreased by a consolidation, combination, reverse stock split or reclassification of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the
number of shares of Common Stock issuable on exercise of each Warrant shall be decreased in proportion to such decrease in outstanding shares of Common Stock. 

4.3 Extraordinary Dividends. If the Company, at any time while the Warrants are outstanding and unexpired, shall pay a dividend or
make a distribution in cash, securities or other assets to the holders of the Common Stock or other shares of the Company’s capital stock into which the Warrants are convertible (an “Extraordinary Dividend”), then the Warrant
Price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash and the fair market value (as determined by the Company’s Board of Directors, in good faith) of any securities or
other assets paid in respect of such Extraordinary Dividend divided by all outstanding shares of the Company at such time (whether or not any shareholders waived their right to receive such dividend); provided, however, that none of the following
shall be deemed an Extraordinary Dividend for purposes of this provision: (a) any adjustment described in subsection 4.1 above, (b) any cash dividends or cash distributions which, when combined on a per share basis with all other cash
dividends and cash distributions paid on the Common Stock during the 365-day period ending on the date of declaration of such dividend or distribution does not exceed $0.50 per share (taking into
account all of the outstanding shares of the Company at such time (whether or not any shareholders waived their right to receive such dividend) and as adjusted to appropriately reflect any of the events referred to in other subsections of this
Section 4 and excluding cash dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the number of shares of Common Stock issuable on exercise of each Warrant) but only with respect to the amount of the
aggregate cash dividends or cash distributions equal to or less than $0.50, (c) any payment to satisfy the redemption rights of the holders of the shares of Common Stock in connection with a proposed initial Business Combination or certain
amendments to the Company’s Amended and Restated Certificate of Incorporation (as described in the Registration Statement) or (d) any payment in connection with the Company’s liquidation and the distribution of its assets upon its
failure to consummate a Business Combination. Solely for purposes of illustration, if the Company, at a time while the Warrants are outstanding and unexpired, pays a cash dividend of $0.35 and previously paid an aggregate of $0.40 of cash dividends
and cash distributions on the Common Stock during the 365-day period ending on the date of declaration of such $0.35 dividend, then the Warrant Price will be decreased, effectively immediately after
the effective date of such $0.35 dividend, by $0.25 (the absolute value of the difference between $0.75 (the aggregate amount of all cash dividends and cash distributions paid or made in
such 365-day period, including such $0.35 dividend) and $0.50 (the greater of (x) $0.50 and (y) the aggregate amount of all cash dividends and cash distributions paid or made in such 365-day period prior to such $0.35 dividend)). Furthermore, solely for the purposes of illustration, if following the closing of the Company’s initial Business Combination, there were 100,000,000
shares outstanding and the Company paid a $1.00 dividend to 17,500,000 of such shares (with the remaining 82,500,000 shares waiving their right to receive such dividend), then no adjustment to the Warrant Price would occur as a $17.5 million
dividend payment divided by 100,000,000 shares equals $0.175 per share which is less than $0.50 per share. 
 4.4 Adjustments in
Exercise Price. Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted, as provided in Sections 4.1 and 4.2 above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such
Warrant Price immediately prior to such adjustment by a fraction (x) the numerator of which shall be the number of shares of Common Stock purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the
denominator of which shall be the number of shares of Common Stock so purchasable immediately thereafter. 

  
 5 

 4.5. Replacement of Securities upon Reorganization, etc. In case of any
reclassification or reorganization of the outstanding shares of Common Stock (other than a change covered by Section 4.1, 4.2 or 4.3 hereof or that solely affects the par value of the Common Stock), or in the case of any merger or consolidation
of the Company with or into another corporation (other than a consolidation or merger in which the Company is the continuing corporation and that does not result in any reclassification or reorganization of the outstanding shares of Common Stock),
or in the case of any sale or conveyance to another corporation or entity of the assets or other property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the Warrant holders shall
thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise of the
rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or
transfer, that the Warrant holder would have received if such Warrant holder had exercised his, her or its Warrant(s) immediately prior to such event. If any reclassification also results in a change in the Common Stock covered by Section 4.1,
4.2 or 4.3, then such adjustment shall be made pursuant to Sections 4.1, 4.2, 4.3, 4.4 and this Section 4.5. The provisions of this Section 4.5 shall similarly apply to successive reclassifications, reorganizations, mergers or
consolidations, sales or other transfers. In no event will the Warrant Price be reduced to less than the par value per share issuable upon exercise of the Warrant. 

4.6. Issuance in connection with a Business Combination. If, in connection with a Business Combination, the Company
(a) issues additional shares of Common Stock or equity-linked securities at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price as determined by the Company’s Board of
Directors, in good faith, and in the case of any such issuance to the Company’s initial stockholders, or their affiliates, without taking into account any founders shares held by them prior to such issuance), (b) the aggregate gross proceeds
from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Business Combination on the date of the consummation of such Business Combination (net of redemptions), and (c) the
Fair Market Value (as defined below) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Fair Market Value or (ii) the price at which the Company
issues the Common Stock or equity-linked securities, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Fair Market Value and the price at which the Company issues Common
Stock or equity-linked securities. Solely for purposes of this Section 4.6, the “Fair Market Value” shall mean the volume weighted average reported trading price of the Common Stock for the twenty (20) trading days
starting on the trading day prior to the date of the consummation of the Business Combination. 
 4.7 Notices of Changes in Warrant.
Upon every adjustment of the Warrant Price or the number of shares issuable upon exercise of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting from such adjustment and
the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence
of any event specified in Sections 4.1, 4.2, 4.3, 4.4, 4.5, or 4.6, then, in any such event, the Company shall give written notice to each Warrant holder, at the last address set forth for such holder in the Warrant Register, of the record date or
the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event. 

4.8. No Fractional Warrants or Shares. Notwithstanding any provision contained in this Agreement to the contrary, the Company
shall not issue fractional shares upon exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a
share, the Company shall, upon such exercise, round up to the nearest whole number of shares of Common Stock to be issued to the Warrant holder. 

  
 6 

 4.9. Form of Warrant. The form of Warrant need not be changed because of any
adjustment pursuant to this Section 4, and Warrants issued after such adjustment may state the same Warrant Price and the same number of shares as is stated in the Warrants initially issued pursuant to this Agreement. However, the Company may
at any time in its sole discretion make any change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange or substitution
for an outstanding Warrant or otherwise, may be in the form as so changed. 
 4.10 Other Events. In case any event shall occur
affecting the Company as to which none of the provisions of preceding subsections of this Section 4 are strictly applicable, but which would require an adjustment to the terms of the Warrants in order to (i) avoid an adverse impact on the
Warrants and (ii) effectuate the intent and purpose of this Section 4, then, in each such case, the Company shall appoint a firm of independent public accountants, investment banking or other appraisal firm of recognized national standing,
which shall give its opinion as to whether or not any adjustment to the rights represented by the Warrants is necessary to effectuate the intent and purpose of this Section 4 and, if they determine that an adjustment is necessary, the terms of
such adjustment. The Company shall adjust the terms of the Warrants in a manner that is consistent with any adjustment recommended in such opinion. 

5. Transfer and Exchange of Warrants. 

5.1. Registration of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon
the Warrant Register, upon surrender of such Warrant for transfer, properly endorsed with signatures, in the case of certificated Warrants, properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new
Warrant representing an equal aggregate number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. In the case of certificated Warrants, the Warrants so cancelled shall be delivered by the Warrant Agent to the
Company from time to time upon request. 
 5.2. Procedure for Surrender of Warrants. Warrants may be surrendered to the Warrant
Agent, either in certificated form or in book entry position, together with a written request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants, or book entry positions, as requested
by the registered holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that in the event that a Warrant surrendered for transfer bears a restrictive legend, the Warrant Agent shall not cancel
such Warrant and issue new Warrants in exchange therefor until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.

 5.3. Fractional Warrants. The Warrant Agent shall not be required to effect any registration of transfer or exchange which
will result in the issuance of a warrant certificate or book-entry position for a fraction of a Warrant. 
 5.4. Service
Charges. No service charge shall be made for any exchange or registration of transfer of Warrants. 
 5.5. Warrant Execution and
Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company,
whenever required by the Warrant Agent, will supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose. 

5.6. Private Warrants and Working Capital Warrants. The Warrant Agent shall not register any transfer of Private Warrants or
Working Capital Warrants until after the consummation by the Company of an initial Business Combination, except for transfers (i) among the initial shareholders or to the initial shareholders’ or the Company’s officers, directors,
consultants or their affiliates, (ii) to a holder’s shareholders or members upon the holder’s liquidation, in each case if the holder is an entity, (iii) by bona fide gift to a member of the holder’s immediate family or to a
trust, the beneficiary of which is the holder or a member of the holder’s immediate family, in each case for estate planning purposes, (iv) by virtue of the laws of descent and distribution upon death, (v) pursuant to a qualified
domestic relations order, (vi) to the Company for no value for cancellation in connection with the consummation of a Business Combination, (vii) in connection with the consummation of a Business Combination by private sales at prices no
greater than the price at which the Private Warrants were originally purchased, (viii) in the event of the Company’s liquidation prior to its consummation of an initial Business Combination or (ix) in the event

  
 7 

 
that, subsequent to the consummation of an initial Business Combination, the Company completes a liquidation, merger, share exchange or other similar transaction which results in all of the
Company’s shareholders having the right to exchange their shares of Common Stock for cash, securities or other property, in each case (except for clauses (vi), (viii) or (ix) or with the Company’s prior written consent) on the
condition that prior to such registration for transfer, the Warrant Agent shall be presented with written documentation pursuant to which each transferee (each, a “Permitted Transferee”) or the trustee or legal guardian for such
transferee agrees to be bound by the transfer restrictions contained in this section and any other applicable agreement the transferor is bound by. 

5.7. Transfers prior to Detachment. Prior to the Detachment Date, the Public Warrants may be transferred or exchanged only
together with the Unit in which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such Unit. Furthermore, each transfer of a Unit on the register relating to such Units shall operate
also to transfer the Warrants included in such Unit. Notwithstanding the foregoing, the provisions of this Section 5.7 shall have no effect on any transfer of Warrants on or after the Detachment Date. 

6. Redemption. 

6.1. Redemption. Not less than all of the outstanding Warrants may be redeemed, at the option of the Company, at any time during
the Exercise Period, at the office of the Warrant Agent, upon the notice referred to in Section 6.2, at the price of $0.01 per Warrant (“Redemption Price”), provided that the closing price of the Common Stock equals or exceeds
$18.00 per share (subject to adjustment in accordance with Section 4 hereof), on each of twenty (20) trading days within any thirty (30) trading day period commencing after the Warrants become exercisable and ending on the third
trading day prior to the date on which notice of redemption is given and provided that there is an effective registration statement covering the Common Stock issuable upon exercise of the Warrants, and a current prospectus relating thereto,
available throughout the 30-day redemption or the Company has elected to require the exercise of the Warrants on a “cashless basis” pursuant to subsection 3.3.1(b); provided, however, that
if and when the Warrants become redeemable by the Company, the Company may not exercise such redemption right if the issuance of Common Stock upon exercise of the Warrants is not exempt from registration or qualification under applicable state blue
sky laws or the Company is unable to effect such registration or qualification. 
 6.2. Date Fixed for, and Notice of,
Redemption. In the event the Company shall elect to redeem all of the Warrants that are subject to redemption, the Company shall fix a date for the redemption (the “Redemption Date”). Notice of redemption shall be mailed by
first class mail, postage prepaid, by the Company not less than thirty (30) days prior to the Redemption Date to the registered holders of the Warrants to be redeemed at their last addresses as they shall appear on the registration books. Any
notice mailed in the manner herein provided shall be conclusively presumed to have been duly given whether or not the registered holder received such notice. 

6.3. Exercise After Notice of Redemption. The Warrants may be exercised, for cash (or on a “cashless basis” in
accordance with Section 3 of this Agreement) at any time after notice of redemption shall have been given by the Company pursuant to Section 6.2 hereof and prior to the Redemption Date. In the event the Company determines to require all
holders of Warrants to exercise their Warrants on a “cashless basis” pursuant to Section 3.3.1(b), the notice of redemption will contain the information necessary to calculate the number of shares of Common Stock to be received upon
exercise of the Warrants, including the “Fair Market Value” in such case. On and after the Redemption Date, the record holder of the Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Redemption
Price. 
 7. Other Provisions Relating to Rights of Holders of Warrants. 

7.1. No Rights as Stockholder. A Warrant does not entitle the registered holder thereof to any of the rights of a stockholder of
the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent or to receive notice as shareholders in respect of the meetings of shareholders or the election
of directors of the Company or any other matter. 
 7.2. Lost, Stolen, Mutilated, or Destroyed Warrants. If any Warrant is lost,
stolen, mutilated, or destroyed, the Company and the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new
Warrant of like 

  
 8 

 
denomination, tenor, and date as the Warrant so lost, stolen, mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the
allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone. 
 7.3. Reservation of Common
Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued shares of Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

 7.4. Registration of Common Stock. The Company agrees that as soon as practicable after the closing of its initial Business
Combination, it shall use its best efforts to file with the Securities and Exchange Commission a registration statement for the registration, under the Act, of the Common Stock issuable upon exercise of the Warrants, and it shall use its best
efforts to take such action as is necessary to register or qualify for sale, in those states in which the Warrants were initially offered by the Company and in those states where holders of Warrants then reside, the Common Stock issuable upon
exercise of the Warrants, to the extent an exemption is not available. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating
thereto, until the expiration of the Warrants in accordance with the provisions of this Agreement. If any such registration statement has not been declared effective by the 60th day following the closing of the Business Combination, holders of the
Warrants shall have the right, during the period beginning on the 61st day after the closing of the Business Combination and ending upon such registration statement being declared effective by the Securities and Exchange Commission, and during any
other period when the Company shall fail to have maintained an effective registration statement covering the Common Stock issuable upon exercise of the Warrants, to exercise such Warrants on a “cashless basis” as determined in accordance
with Section 3.3.1(c). The Company shall provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm with securities law experience) stating that (i) the exercise of the Warrants on a cashless
basis in accordance with this Section 7.4 is not required to be registered under the Act and (ii) the Common Stock issued upon such exercise will be freely tradable under U.S. federal securities laws by anyone who is not an affiliate (as
such term is defined in Rule 144 under the Act) of the Company and, accordingly, will not be required to bear a restrictive legend. For the avoidance of any doubt, unless and until all of the Warrants have been exercised on a cashless basis, the
Company shall continue to be obligated to comply with its registration obligations under the first three sentences of this Section 7.4. The provisions of this Section 7.4 may not be modified, amended, or deleted without the prior written
consent of the Representative. 
 8. Concerning the Warrant Agent and Other Matters. 

8.1. Payment of Taxes. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company
or the Warrant Agent in respect of the issuance or delivery of Common Stock upon the exercise of Warrants, but the Company shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares of Common Stock. 

8.2. Resignation, Consolidation, or Merger of Warrant Agent. 

8.2.1. Appointment of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its
duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise,
the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after it has been notified in writing of such resignation or
incapacity by the Warrant Agent or by the holder of the Warrant (who shall, with such notice, submit his Warrant for inspection by the Company), then the holder of any Warrant may apply to the Supreme Court of the State of New York for the County of
New York for the appointment of a successor Warrant Agent at the Company’s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the State of New
York, in good standing and having its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state
authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent
hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, 

  
 9 

 
the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such
predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such
successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations. 
 8.2.2. Notice of Successor
Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such
appointment. 
 8.2.3. Merger or Consolidation of Warrant Agent. Any corporation into which the Warrant Agent may be merged or
with which it may be consolidated or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further act. 

8.3. Fees and Expenses of Warrant Agent. 

8.3.1. Remuneration. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent
hereunder and will reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder. 

8.3.2. Further Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed,
acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions of this Agreement. 

8.4. Liability of Warrant Agent. 

8.4.1. Reliance on Company Statement. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem
it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be
deemed to be conclusively proved and established by a statement signed by the Chief Executive Officer or Chairman of the Board of Directors of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any
action taken or suffered in good faith by it pursuant to the provisions of this Agreement. 
 8.4.2. Indemnity. The Warrant
Agent shall be liable hereunder only for its own fraud, gross negligence, willful misconduct or bad faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and
reasonable counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement except as a result of the Warrant Agent’s fraud, gross negligence, willful misconduct, or bad faith. 

8.4.3. Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect
to the validity or execution of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant; nor shall it be responsible to
make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by
any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement, the Amended and Restated Certificate of Incorporation of the Company, or
any Warrant or as to whether any Common Stock will, when issued, be valid and fully paid and nonassessable. 
 8.5. Acceptance of
Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to
Warrants exercised and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase of shares of Common Stock through the exercise of Warrants. 

  
 10 

 9. Miscellaneous Provisions. 

9.1. Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall
bind and inure to the benefit of their respective successors and assigns. 
 9.2. Notices. Any notice, statement or demand
authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any Warrant to or on the Company shall be sufficiently given (i) if by email when the email is sent, (ii) if by hand or overnight delivery, when so
delivered, or (iii) if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company with the Warrant Agent), as
follows: 
 OPY I Acquisition Corp. 

85 Broad Street 

New York, New York 10004 

Attn: Jonathan B. Siegel, Chief Executive Officer 

E-mail: 

Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent
shall be sufficiently given (i) if by email, when the email is sent, (ii) if by hand or overnight delivery, when so delivered, or (iii) if sent by certified mail or private courier service within five days after deposit of such
notice, postage prepaid, addressed (until another address is filed in writing by the Warrant Agent with the Company), as follows: 

Continental Stock Transfer & Trust Company 

1 State Street 

New York, New York 10004 

Attn: Compliance Department 

with a copy in each case to: 

Loeb & Loeb LLP 

345 Park Avenue 

New York, NY 10154 

Attn: Mitchell Nussbaum 

E-mail: mnussbaum@loeb.com 

and 
 White & Case LLP

 1221 Avenue of the Americas 

New York, NY 10020 

Attn: Stuart Bressman 
 and 

Oppenheimer & Co. Inc. 

85 Broad Street 

New York, NY 10004 

Attn: General Counsel 

9.3. Applicable Law. The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed in all
respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim
against it arising out of or relating in any way to this Agreement shall be 

  
 11 

 
brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York. The Company hereby waives any objection that such courts
represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set
forth in Section 9.2 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. 

9.4. Persons Having Rights under this Agreement. Nothing in this Agreement expressed and nothing that may be implied from any of
the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto and the registered holders of the Warrants and, for the purposes of Sections 7.4, 9.4 and 9.8 hereof, the
Representative, any right, remedy, or claim under or by reason of this Warrant Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. The Representative shall be deemed to be a third-party beneficiary of this Agreement
with respect to Sections 7.4, 9.4 and 9.8 hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Warrant Agreement shall be for the sole and exclusive benefit of the parties hereto (and the Representative with
respect to the Sections 7.4, 9.4 and 9.8 hereof) and their successors and assigns and of the registered holders of the Warrants. 

9.5. Examination of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at the office of
the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the registered holder of any Warrant. The Warrant Agent may require any such holder to submit his Warrant for inspection by it. 

9.6. Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such
counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. 

9.7. Effect of Headings. The section headings herein are for convenience only and are not part of this Agreement and shall not
affect the interpretation thereof. 
 9.8 Amendments. This Agreement may be amended by the parties hereto without the consent of
any registered holder for the purpose of curing any ambiguity, or of curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this
Agreement as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the interest of the registered holders. All other modifications or amendments, including any amendment to increase the Warrant Price or
shorten the Exercise Period, shall require the written consent or vote of the registered holders of (i) a majority of the then outstanding Public Warrants if such modification or amendment is being undertaken prior to, or in connection with,
the consummation of a Business Combination or (ii) a majority of the then outstanding Warrants if such modification or amendment is being undertaken after the consummation of a Business Combination. Notwithstanding the foregoing, the Company
may lower the Warrant Price or extend the duration of the Exercise Period pursuant to Sections 3.1 and 3.2, respectively, without the consent of the registered holders. The provisions of this Section 9.8 may not be modified, amended or deleted
without the prior written consent of the Representative. 
 9.9 Trust Account Waiver. The Warrant Agent acknowledges and agrees
that it shall not make any claims or proceed against the trust account established by the Company in connection with the Public Offering (as more fully described in the Registration Statement) (“Trust Account”), including by way of set-off, and shall not be entitled to any funds in the Trust Account under any circumstance. In the event that the Warrant Agent has a claim against the Company under this Agreement, the Warrant Agent
will pursue such claim solely against the Company and not against the property held in the Trust Account. 
 9.10 Severability.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any
such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and
enforceable. 

  
 12 

 [signature page follows] 

  
 13 

 IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of the
day and year first above written. 
  

			
	OPY ACQUISITION CORP. I
		
	By:	 	  

		 	Name: Jonathan B. Siegel
		 	Title: Chief Executive Officer
	
	 CONTINENTAL STOCK TRANSFER & TRUST COMPANY

		
	By:	 	  

		 	Name:
		 	Title:

 [Signature Page to Warrant Agreement] 

  
 14 

 EXHIBIT A 

WARRANT CERTIFICATE 

  
 15 

 EXHIBIT B 

LEGEND FOR PRIVATE PLACEMENT WARRANTS 
 THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN THE LETTER AGREEMENT BY AND AMONG OPY ACQUISITION CORP. I
(THE “COMPANY”), OPY ACQUISITION LLC I AND THE OTHER PARTIES THERETO, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE THAT IS THIRTY (30) DAYS AFTER THE DATE UPON WHICH THE
COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN SECTION 5.6 OF THE WARRANT AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO
BE SUBJECT TO SUCH TRANSFER PROVISIONS. 
 SECURITIES EVIDENCED BY THIS CERTIFICATE AND SHARES OF THE COMMON STOCK OF THE COMPANY ISSUED UPON EXERCISE OF
SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION RIGHTS UNDER A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY. 

  
 16EX-4.2

 Exhibit 4.2 

SONENDO, INC. 
 FIFTH
AMENDED AND RESTATED VOTING AGREEMENT 
 THIS FIFTH AMENDED AND RESTATED VOTING AGREEMENT (this “Agreement”) is made as
of December 10, 2019, by and among Sonendo, Inc., a Delaware corporation (the “Company”), the stockholders of the Company listed on Exhibit A, together with any subsequent stockholders who become parties hereto pursuant
to Section 7(b) (collectively, the “Stockholders”), and the holders of shares of Preferred Stock (as defined below) listed on Exhibit B (collectively, the “Investors” and
individually, the “Investor”). The Stockholders and the Investors are referred herein collectively as “Voting Parties.” 

RECITALS 
 WHEREAS, the
Stockholders and certain of the Investors own shares of the Company’s Common Stock, $0.001 par value per share (the “Common Stock”), Series A-1 Preferred Stock, $0.001 par value per share
(“Series A-1 Preferred Stock”), Series B Preferred Stock, $0.001 par value per share (“Series B Preferred Stock”), Series C Preferred Stock, $0.001 par value per share
(“Series C Preferred Stock”), Series C-1 Preferred Stock, $0.001 par value per share (“Series C-1 Preferred Stock”), Series D Preferred
Stock, $0.001 par value per share (“Series D Preferred Stock”), and/or Series E Preferred Stock, $0.001 par value per share (“Series E Preferred Stock,” and collectively referred to herein with the Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock as the “Preferred Stock”);

 WHEREAS, the Company, certain of the Investors and the Stockholders are parties to that certain Fourth Amended and Restated Voting
Agreement, dated as of November 15, 2018 (the “Prior Voting Agreement”); 
 WHEREAS, certain of the Investors are
purchasing shares of Series E Preferred Stock pursuant to that certain Series E Preferred Stock Purchase Agreement of even date herewith (the “Purchase Agreement”); 

WHEREAS, in connection with the purchase and sale of shares of the Company’s Series E Preferred Stock pursuant to the Purchase Agreement,
the Company and the other parties to the Prior Voting Agreement desire to amend and restate the Prior Voting Agreement in its entirety; 

WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement; and 

WHEREAS, in connection with the consummation of the financing provided for in the Purchase Agreement, the Company, the Stockholders and the
Investors have agreed to provide for the future voting of their shares of the voting capital stock of the Company as set forth below. 

 AGREEMENT 

The parties hereby agree as follows: 

1. Voting of Shares. During the term of this Agreement, the Voting Parties each agree to vote all shares of the Company’s voting
securities now or hereafter owned by them, whether beneficially or otherwise, or as to which they have voting power (the “Shares”) in accordance with and to give effect to the provisions of this Agreement. 

2. Election of Board of Directors. 

(a) Board Representation. At each annual meeting of the stockholders of the Company, or at any meeting of the stockholders of the
Company at which members of the Board of Directors of the Company (the “Board”) are to be elected, or whenever members of the Board are to be elected by written consent, the Voting Parties agree to vote or act with respect to their
Shares so as to elect to the Board: 
 (i) For so long as Fjord Capital Partners I, L.P. (“Fjord”), together with any
Affiliates, owns at least 10% of the shares of Preferred Stock originally purchased by Fjord and its Affiliates from the Company (as calculated on an as converted to Common Stock basis and as adjusted for stock splits, dividends and the like) (the
“Fjord Minimum Shares”), one (1) individual designated by Fjord, who shall initially be Olav B. Bergheim, as a Preferred Stock Director (as defined in the Company’s Amended and Restated Certificate of Incorporation, as
amended (the “Restated Certificate”)); provided however that in the event that Fjord, together with its Affiliates, ceases to own at least the Fjord Minimum Shares, the Fjord designee shall be designated by the holders of at least
seventy-five percent (75%) of the combined voting power of the Preferred Stock; 
 (ii) For so long as OrbiMed Private Investments IV, LP
(“OrbiMed”), together with any Affiliates, owns at least 10% of the shares of Preferred Stock originally purchased by OrbiMed and its Affiliates from the Company (as calculated on an as converted to Common Stock basis and as
adjusted for stock splits, dividends and the like) (the “OrbiMed Minimum Shares”), one (1) individual designated by OrbiMed, who shall initially be Vince Burgess, as a Preferred Stock Director; provided however that in
the event that OrbiMed, together with its Affiliates, ceases to own at least the OrbiMed Minimum Shares, the OrbiMed designee shall be designated by the holders of at least seventy-five percent (75%) of the combined voting power of the Preferred
Stock; 
 (iii) For so long as Meritech Capital Partners IV, L.P. (“Meritech”), together with any Affiliates, owns at
least 10% of the shares of Preferred Stock originally purchased by Meritech and its Affiliates from the Company (as calculated on an as converted to Common Stock basis and as adjusted for stock splits, dividends and the like) (the “Meritech
Minimum Shares”), one (1) individual designated by Meritech, who shall initially be Paul Madera, as a Preferred Stock Director; provided however that in the event that Meritech, together with its Affiliates, ceases to own at least the
Meritech Minimum Shares, the Meritech designee shall be designated by the holders of at least seventy-five percent (75%) of the combined voting power of the Preferred Stock; 

  
 - 2 - 

 (iv) For so long as General Atlantic (SOI), L.P. (collectively, “General
Atlantic”), together with any Affiliates, owns at least 10% of the shares of Preferred Stock originally purchased by General Atlantic and its Affiliates from the Company (as calculated on an as converted to Common Stock basis and as
adjusted for stock splits, dividends and the like) (the “General Atlantic Minimum Shares”), two (2) individuals designated by General Atlantic (each a “General Atlantic Director”, and collectively, the
“General Atlantic Directors”), who shall initially be Alex Crisses and Cory Eaves, each as a Preferred Stock Director; provided however that in the event that General Atlantic, together with its Affiliates, ceases to own at least
the General Atlantic Minimum Shares, the General Atlantic designees shall be designated by the holders of at least seventy-five percent (75%) of the combined voting power of the Preferred Stock; 

(v) For so long as EW Healthcare Partners Fund 2, L.P. (“EW Healthcare”), together with any Affiliates, owns at least 10% of
the shares of Preferred Stock originally purchased by EW Healthcare and its Affiliates from the Company (as calculated on an as converted to Common Stock basis and as adjusted for stock splits, dividends and the like) (the “EW Healthcare
Minimum Shares”), one (1) individual designated by EW Healthcare, who shall initially be Brooks Andrews, as a Preferred Stock Director; provided however that in the event that EW Healthcare, together with its Affiliates, ceases to own
at least the EW Healthcare Minimum Shares, the EW Healthcare designee shall be designated by the holders of at least seventy-five percent (75%) of the combined voting power of the Preferred Stock; 

(vi) The then-current Chief Executive Officer of the Company, who shall initially be Bjarne Bergheim (the “CEO Director”),
provided that if for any reason the CEO Director shall cease to serve as the Chief Executive Officer of the Company, each of the Voting Parties shall promptly vote their respective Shares (i) to remove the former Chief Executive Officer from
the Board if such person has not resigned as a member of the Board and (ii) to elect such person’s replacement as Chief Executive Officer of the Company as the new CEO Director; 

(vii) Two (2) representatives designated by the Board, with the approval of a majority of the Preferred Stock Directors, who are not
employed by the Company or otherwise affiliated with the Company or any stockholder holding one percent (1%) or more of the Company’s then outstanding capital stock (each an “Independent Director”), who shall initially be
Thomas R. Engels and Daniel Even (the “Independent Directors”); provided, however, that prior to March 19, 2020, a majority of the Preferred Stock Directors (including Preferred Stock Directors designated by at least two
(2) out of the three (3) of OrbiMed, Meritech and General Atlantic) may, by written notice to the Company, reduce the then authorized number of directors of the Company and the number of Independent Directors by one (1), and the remaining
Independent Director(s) shall be designated by the Board, with the approval of a majority of the Preferred Stock Directors; and 
 (viii)
One (1) representative designated by EW Healthcare, with the approval of the Board, including a majority of the Preferred Stock Directors (excluding any Preferred Stock Director designated by EW Healthcare), who is an industry expert with
operating experience (the “Industry Expert Director”); provided however that in the event that EW Healthcare, together with its Affiliates, ceases to own at least the EW Healthcare Minimum Shares, the Industry Expert Director shall
be designated by the Board, with the approval of a majority of the Preferred Stock Directors. 

  
 - 3 - 

 (b) Committee Membership. Each Preferred Stock Director shall be entitled in such
person’s discretion to be a member of any committee of the Board. 
 (c) Appointment of Directors. In the event of the
resignation, death, removal or disqualification of a director selected under this Section 2, a new director shall promptly be designated and elected following the procedure originally used to elect the director being
replaced and, after written notice of the designation has been given by the Company to the Voting Parties following the director’s designation (and such nominee has been designated as provided in this Section 2), each
Voting Party shall vote its shares of capital stock of the Company to elect such designee to the Board. 
 (d) Removal. A director
elected under this Section 2 may be removed at any time and from time to time, with or without cause (subject to the Bylaws of the Company as in effect from time to time and any requirements of law) in the following manner:
in the case of a director elected under Section 2(a)(i), by Fjord or, in the event that Fjord, together with its Affiliates, ceases to own at least the Fjord Minimum Shares, by the holders of at least
seventy-five percent (75%) of the combined voting power of the Preferred Stock; in the case of a director elected under Section 2(a)(ii), by OrbiMed or, in the event that OrbiMed, together with its Affiliates, ceases to own
at least the OrbiMed Minimum Shares, by the holders of at least seventy-five percent (75%) of the combined voting power of the Preferred Stock; in the case of a director elected under Section 2(a)(iii), by Meritech or, in
the event that Meritech, together with its Affiliates, ceases to own at least the Meritech Minimum Shares, by the holders of at least seventy-five percent (75%) of the combined voting power of the Preferred Stock; in the case of a director elected
under Section 2(a)(iv), by General Atlantic or, in the event that General Atlantic, together with its Affiliates, ceases to own at least the General Atlantic Minimum Shares, by the holders of at least seventy-five percent
(75%) of the combined voting power of the Preferred Stock; in the case of a director elected under Section 2(a)(v), by EW Healthcare or, in the event that EW Healthcare, together with its Affiliates, ceases to own at least
the EW Healthcare Minimum Shares, by the holders of at least seventy-five percent (75%) of the combined voting power of the Preferred Stock; in the case of a director elected under Section 2(a)(vi) who is the then-current
Chief Executive Officer, by a majority of the Company’s Common Stock and Preferred Stock, voting together as a single class on an as-converted to Common Stock basis, it being understood that the Board has
sole discretion to replace the Company’s Chief Executive Officer pursuant to the Bylaws of the Company; and in the case of a director elected under Section 2(a)(vii) or Section 2(a)(viii), by
holders of at least sixty percent (60%) of the combined voting power of the Preferred or by the Board, with the approval of a majority of the Preferred Stock Directors. 

(e) For purposes of this Agreement, “Person” shall mean an individual, a corporation, a partnership, a trust or
unincorporated organization or any other entity or organization 

  
 - 4 - 

 (f) For purposes of this Agreement, “Affiliate” shall mean with respect to
any Person, any Person which directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, including without limitation any general partner, managing member, officer or director of
such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person. 

(g) The Company will promptly reimburse all reasonable expenses of the non-employee directors
appointed pursuant to this Section 2 incurred in connection with their travel to and attending meetings of the Board, committees of the Board and, with the separate approval of the Board, other meetings or events attended
on behalf of the Company, including without limitation reasonable travel and accommodation expenses. 
 3. Vote to Increase Authorized
Stock. 
 (a) Common Stock. Each Voting Party agrees to vote or cause to be voted all Shares owned by such Voting Party, as the
case may be, or over which such Voting Party has voting control, from time to time and at all times, in whatever manner as shall be necessary to increase the number of authorized shares of Common Stock from time to time to ensure that there will be
sufficient shares of Common Stock available for conversion of all of the shares of Preferred Stock outstanding at any given time. 
 (b)
Preferred Stock. Each Voting Party agrees to vote or cause to be voted all Shares owned by such Voting Party, as the case may be, or over which such Voting Party has voting control, from time to time and at all times, in whatever manner as
shall be necessary to increase the number of authorized shares of Series E Preferred Stock from time to time to ensure that there will be sufficient shares of Series E Preferred Stock available for sale and issuance pursuant to Section 2.9 of
that certain Third Amended and Restated Investors’ Rights Agreement of even date herewith, by and among the Company and certain of the stockholders of the Company (the “Rights Agreement”). 

4. Drag-Along Right. 

(a) Definitions. A “Sale of the Company” shall mean either: (a) a transaction or series of related transactions
in which a Person, or a group of related Persons, acquires from stockholders of the Company (the “Selling Stockholders”) shares representing more than fifty percent (50%) of the outstanding voting power of the Company (a
“Stock Sale”); or (b) a transaction that qualifies as a “Liquidating Transaction” as defined in Section 2(a)(v)(B) or (C) under Part B of Article IV of the Restated Certificate. 

(b) Actions to be Taken. In the event that (i) the holders of at least sixty percent (60%) of the combined voting power of the
Preferred Stock, and (ii) the Board of Directors, each approve a Sale of the Company in writing, then each Voting Party and the Company hereby agree: 

(i) if such transaction requires stockholder approval, with respect to all Shares that such Voting Party owns or over which such Voting Party
otherwise exercises voting power, to vote (in person, by proxy or by action by written consent, as applicable) all such Shares in favor of, and adopt, such Sale of the Company (together with any related amendment to the Restated Certificate required
in order to implement such Sale of the Company, but subject to the rights of the holders of any series of Preferred Stock set forth therein) and to vote in opposition to any and all other proposals that could delay or impair the ability of the
Company to consummate such Sale of the Company; 

  
 - 5 - 

 (ii) if such transaction is a Stock Sale, to sell the same proportion of shares of capital
stock of the Company beneficially held by such Voting Party as is being sold by the Selling Stockholders to the Person to whom the Selling Stockholders propose to sell their Shares, and, subject to Section 4(c) below, on
the same terms and conditions as the Selling Stockholders; 
 (iii) to execute and deliver all related documentation (except for any non-competition or non-solicitation agreement or other agreement that directly or indirectly limits or restricts any Voting Party’s or its Affiliates’ business or
activities) and take such other action in support of the Sale of the Company as shall reasonably be requested by the Company or the Selling Stockholders in order to carry out the terms and provisions of this Section 4,
including without limitation executing and delivering instruments of conveyance and transfer, and any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver (it being understood that no Voting Party shall be
required to execute a consent or waiver with the effect of waiving any rights of such Voting Party or the series of Preferred Stock held by it), governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible
liens, claims and encumbrances) and any similar or related documents; 
 (iv) not to deposit, and to cause their Affiliates not to deposit,
except as provided in this Agreement, any Shares of the Company owned by such party or Affiliate in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do
so by the acquiror in connection with the Sale of the Company; 
 (v) to refrain from exercising any dissenters’ rights or rights of
appraisal under applicable law at any time with respect to such Sale of the Company; 
 (vi) if the consideration to be paid in exchange
for the Shares pursuant to this Section 4 includes any securities and due receipt thereof by any Voting Party would require under applicable law (x) the registration or qualification of such securities or of any person
as a broker or dealer or agent with respect to such securities or (y) the provision to any Voting Party of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited
investors” as defined in Regulation D promulgated under the Securities Act of 1933, as amended, the Company may cause to be paid to any such Voting Party in lieu thereof, against surrender of the Shares which would have otherwise been sold by
such Voting Party, an amount in cash equal to the fair value (as determined in good faith by the Company) of the securities which such Voting Party would otherwise receive as of the date of the issuance of such securities in exchange for the Shares;
and 

  
 - 6 - 

 (vii) in the event that the Selling Stockholders, in connection with such Sale of the
Company, appoint a stockholder representative (the “Stockholder Representative”) with respect to matters affecting the stockholders under the applicable definitive transaction agreements following consummation of such Sale of the
Company, (x) to consent to (1) the appointment of such Stockholder Representative, (2) the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (3) the
payment of such Voting Party’s pro rata portion (from the applicable escrow or expense fund or otherwise) of any and all reasonable fees and expenses to such Stockholder Representative in connection with such Stockholder Representative’s
services and duties in connection with such Sale of the Company and its related service as the representative of the Selling Stockholders, and (y) not to assert any claim or commence any suit against the Stockholder Representative or any other
Voting Party with respect to any action or inaction taken or failed to be taken by the Stockholder Representative in connection with its service as the Stockholder Representative, absent fraud or willful misconduct. 

(c) Exceptions. Notwithstanding the foregoing, a Voting Party will not be required to comply with
Section 4(b) above in connection with any proposed Sale of the Company (the “Proposed Sale”) unless: 

(i) any representations and warranties to be made by such Voting Party in connection with the Proposed Sale are limited to representations and
warranties related to authority, ownership and the ability to convey title to such Shares, including, but not limited to, representations and warranties that (i) the Voting Party holds all right, title and interest in and to the Shares such
Voting Party purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of the Voting Party in connection with the transaction have been duly authorized, if applicable, (iii) the documents to be entered into by
the Voting Party have been duly executed by the Voting Party and delivered to the acquirer and are enforceable against the Voting Party in accordance with their respective terms; and (iv) neither the execution and delivery of documents to be
entered into in connection with the transaction, nor the performance of the Voting Party’s obligations thereunder, will cause a breach or violation of the terms of any agreement to which the Voting Party is a party, or law or judgment, order or
decree of any court or governmental agency applicable to the Voting Party; 
 (ii) the Voting Party shall not be liable for the inaccuracy
of any representation or warranty made by any other person or entity in connection with the Proposed Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to cover breach of representations,
warranties and covenants of the Company as well as breach by any stockholder of any of identical representations, warranties and covenants provided by all stockholders); 

(iii) the liability for indemnification, if any, of such Voting Party in the Proposed Sale and for the inaccuracy of any representations and
warranties made by the Company or its stockholders in connection with such Proposed Sale, is several and not joint with any other Person (except to the extent that funds may be paid out of an escrow established to cover breach of representations,
warranties and covenants of the Company as well as breach by any stockholder of any of identical representations, warranties and covenants provided by all stockholders), and is pro rata in proportion to, and does not exceed, the amount of
consideration paid to such Voting Party in connection with such Proposed Sale; 

  
 - 7 - 

 (iv) upon the consummation of the Proposed Sale, (A) each holder of each class or
series of the Company’s stock will receive the same form of consideration for their shares of such class or series as is received by other holders in respect of their shares of such same class or series of stock, (B) each holder of a
series of Preferred Stock will receive the same amount of consideration per share of such series of Preferred Stock as is received by other holders in respect of their shares of such same series, (C) each holder of Common Stock will receive the
same amount of consideration per share of Common Stock as is received by other holders in respect of their shares of Common Stock, and (D) unless (x) the holders of at least sixty percent (60%) of the combined voting power of the Preferred
Stock and (y) the holders of at least sixty-five percent (65%) of the voting power of the Series E Preferred Stock, elect to receive a lesser amount by written notice given to the Company at least ten (10) days prior to the effective date
of any such Proposed Sale, the aggregate consideration receivable by all holders of the Preferred Stock and Common Stock shall be allocated among the holders of Preferred Stock and Common Stock on the basis of the relative liquidation preferences to
which the holders of each respective series of Preferred Stock and the holders of Common Stock are entitled in a Liquidating Transaction (assuming for this purpose that the Proposed Sale is a Liquidating Transaction) in accordance with the
Company’s Certificate of Incorporation in effect immediately prior to the Proposed Sale; provided, however, that, notwithstanding the foregoing, if the consideration to be paid in exchange for the Shares held by such Voting Party pursuant to
this Section 4(c)(iv) includes any securities and due receipt thereof by any Voting Party would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or
dealer or agent with respect to such securities or (y) the provision to any Voting Party of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited investors”
as defined in Regulation D promulgated under the Securities Act of 1933, as amended, the Company may cause to be paid to any such Voting Party in lieu thereof, against surrender of the Shares held by such Voting Party, which would have otherwise
been sold by such Voting Party, an amount in cash equal to the fair value (as determined in good faith by the Board) of the securities which such Voting Party would otherwise receive as of the date of the issuance of such securities in exchange for
the Shares held by such Voting Party; and 
 (v) subject to clause (iv) above, requiring the same form of consideration to be
available to the holders of any single class or series of capital stock, if any holders of any capital stock of the Company are given an option as to the form and amount of consideration to be received as a result of the Proposed Sale, all holders
of such capital stock will be given the same option; provided, however, that nothing in this clause (v) shall entitle any holder to receive any form of consideration that such holder would be ineligible to receive as a result of such
holder’s failure to satisfy any condition, requirement or limitation that is generally applicable to the Company’s stockholders. 

(d) Restrictions on Sales of Control of the Company. No Voting Party shall be a party to any Stock Sale unless all holders of Preferred
Stock are allowed to participate in such transaction and the consideration received pursuant to such transaction is allocated among the parties thereto in the manner specified in the Company’s Certificate of Incorporation in effect immediately
prior to the Stock Sale (as if such transaction were a Liquidating Transaction), unless (x) the holders of at least sixty percent (60%) of the combined voting power of the Preferred Stock and (y) the holders of at least sixty-five percent
(65%) of the voting power of the Series E Preferred Stock, elect otherwise by written notice given to the Company at least ten (10) days prior to the effective date of any such transaction or series of related transactions. 

  
 - 8 - 

 5. Voting. 

(a) Covenant to Vote. Each Voting Party or its representative shall appear in person or by proxy at any annual or special meeting of
stockholders for the purpose of obtaining a quorum and shall vote the shares of the Company’s capital stock owned or controlled by such Voting Party and entitled to vote upon any matter submitted to a vote of the stockholders of the Company in
a manner so as to be consistent and not in conflict with, and to implement, the terms of this Agreement. Each Voting Party shall execute any and all written consents circulated with regard to any matter reasonably necessary to implement the terms of
this Agreement in a manner that is consistent and not in conflict with, and to implement, the terms of this Agreement. 
 (b) No Voting
or Conflicting Agreements. No Voting Party shall grant any proxy or enter into or agree to be bound by any voting trust with respect to the Shares held by such Voting Party nor shall any Voting Party enter into any stockholder agreements or
arrangements of any kind with any person with respect to their shares inconsistent with the provisions of this Agreement (whether or not such agreements and arrangements are with other stockholders of the Company that are not parties to this
Agreement). The foregoing prohibition includes, but is not limited to, agreements or arrangements with respect to the acquisition, disposition or voting of shares of Preferred Stock and Common Stock held by such Voting Parties, unless the acquiror
or transferee of such shares agrees to be bound by the terms of this Agreement with respect to the voting of such shares. No Voting Party shall act, for any reason, as a member of a group or in concert with any other persons in connection with the
acquisition, disposition or voting of shares of the Company’s capital stock in any manner which is inconsistent with the provisions of this Agreement. 

(c) Irrevocable Proxy and Power of Attorney. Each party to this Agreement hereby constitutes and appoints as the proxies of the party
and hereby grants a power of attorney to the President of the Company, and a designee of the Selling Stockholders, and each of them, with full power of substitution, with respect to the matters set forth herein, including without limitation,
election of persons as members of the Board in accordance with Section 2 hereto, votes to increase authorized shares pursuant to Section 3 hereof and votes regarding any Sale of the Company
pursuant to Section 4 hereof, and hereby authorizes each of them to represent and to vote, if and only if the party (i) fails to vote or (ii) attempts to vote (whether by proxy, in person or by written consent),
in a manner which is inconsistent with the terms of this Agreement, all of such party’s Shares in favor of the election of persons as members of the Board determined pursuant to and in accordance with the terms and provisions of this Agreement
or the increase of authorized shares or approval of any Sale of the Company pursuant to and in accordance with the terms and provisions of Sections 3 and 4, respectively, of this Agreement or to take any action necessary to effect
Sections 3 and 4, respectively, of this Agreement. Each of the proxy and power of attorney granted pursuant to the immediately preceding sentence is given in consideration of the agreements and covenants of the Company and the parties
in connection with the transactions contemplated by this Agreement and, as such, each is coupled with an interest and shall be irrevocable unless and until this Agreement terminates or expires pursuant to Section 8 hereof.
Each party hereto hereby revokes any and all previous proxies or powers of attorney with respect to the Shares and shall not hereafter, unless and until this Agreement terminates or expires pursuant to Section 8 hereof,
purport to grant any other proxy or power of attorney with respect to any of the Shares, deposit any of the Shares into a voting trust or enter into any agreement (other than this Agreement), arrangement or understanding with any person, directly or
indirectly, to vote, grant any proxy or give instructions with respect to the voting of any of the Shares, in each case, with respect to any of the matters set forth herein. 

  
 - 9 - 

 (d) Injunctive Relief. It is acknowledged that it will be impossible to measure in
money the damages that would be suffered if the parties fail to comply with any of the obligations herein imposed on them and that in the event of any such failure, an aggrieved person will be irreparably damaged and will not have an adequate remedy
at law. Any such person shall, therefore, be entitled to injunctive relief, including specific performance, to enforce such obligations, and if any action shall be brought in equity to enforce any of the provisions of this Agreement, none of the
parties hereto shall raise the defense that there is an adequate remedy at law. 
 (e) Remedies Cumulative. All remedies, either
under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 6. Legends. Each
certificate representing any Voting Parties’ shares shall be endorsed by the Company with a legend reading as follows: 
 “THE
SHARES EVIDENCED HEREBY ARE SUBJECT TO A CERTAIN VOTING AGREEMENT, AS THE SAME MAY BE AMENDED, BY AND BETWEEN THE STOCKHOLDER, THE CORPORATION AND CERTAIN HOLDERS OF COMMON AND PREFERRED STOCK OF THE CORPORATION (A COPY OF WHICH MAY BE OBTAINED FROM
THE CORPORATION), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SAID VOTING AGREEMENT.” 

The Company agrees that, during the term of this Agreement, it will not remove, and will not permit to be removed (upon registration of
transfer, reissuance or otherwise), the legend from any such certificate and will place or cause to be placed the legend on any new certificate issued to represent Shares theretofore represented by a certificate carrying the legend. 

7. Covenants of the Company. 

(a) The Company agrees to use its best efforts to ensure that the rights given to the Voting Parties hereunder are effective and that such
parties enjoy the benefits thereof. Such actions include without limitation the use of the Company’s best efforts to cause the nomination and election of the designees as provided in Section 2(a), to enforce the terms
of this Agreement and to inform the Voting Parties of any breach hereof (to the extent the company has knowledge thereof). The Company will not, by any voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be
performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all provisions of this Agreement and in the taking of all such actions as may be necessary, appropriate or reasonably requested by the holders of a
majority of the Shares (assuming exercise and conversion of all outstanding securities) in order to protect the rights of the parties hereunder against impairment and to assist the Voting Parties in the exercise of their rights and the performance
of their obligations hereunder. 

  
 - 10 - 

 (b) Notwithstanding Section 9 below, in the event that after the
date of this Agreement, the Company issues shares of its voting securities to any officer or employee, whose shares constitute one percent (1%) or more of the Company’s then outstanding capital stock (treating for this purpose all shares of
Common Stock issuable upon exercise of or conversion of outstanding options, warrants or convertible securities, as if exercised or converted), the Company shall cause such person to execute a Joinder Agreement in the form attached hereto as
Exhibit C, and such person shall thereby be bound by, and subject to, all the terms and provisions of this Agreement applicable to the Stockholders as a Stockholder hereunder and Exhibit A shall be updated to reflect the addition of
such person as a party hereto. 
 (c) Upon the election of Brooks Andrews as a Preferred Stock Director pursuant to
Section 2(a)(v) above, the Company shall enter into the Company’s standard form of indemnification agreement with Brooks Andrews in his capacity as a member of the Board. 

(d) Upon the election of the Industry Expert Director pursuant to Section 2(a)(viii) above, the Company shall enter
into the Company’s standard form of indemnification agreement with the Industry Expert Director in his capacity as a member of the Board. 

8. Termination. This Agreement shall terminate upon the earlier of (a) the consummation of a Qualified Public Offering (as defined
in the Restated Certificate) or (b) the consummation of a Liquidating Transaction. 
 9. Amendment; Waivers. Any term hereof may
be amended or waived with the written consent of (i) the Company and (ii) the holders of at least sixty percent (60%) of the combined voting power of the Preferred Stock held by the Investors, voting together as a separate class on an as
converted to Common Stock basis; provided, however, that notwithstanding the foregoing, Section 2(a)(i) and the applicable clause of Section 2(d) shall not be amended or
waived without the written consent of Fjord (if then entitled to appoint a director hereunder) or by the holders of at least seventy-five percent (75%) of the combined voting power of the Preferred Stock (if Fjord is not then entitled to appoint a
director hereunder); Section 2(a)(ii) and the applicable clause of Section 2(d) shall not be amended or waived without the written consent of OrbiMed (if then entitled to appoint a director
hereunder) or by the holders of at least seventy-five percent (75%) of the combined voting power of the Preferred Stock (if OrbiMed is not then entitled to appoint a director hereunder); Section 2(a)(iii) and the applicable
clause of Section 2(d) shall not be amended or waived without the written consent of Meritech (if then entitled to appoint a director hereunder) or by the holders of at least seventy-five percent (75%) of the combined
voting power of the Preferred Stock (if Meritech is not then entitled to appoint a director hereunder); Section 2(a)(iv) and the applicable clause of Section 2(d) shall not be amended or waived
without the written consent of General Atlantic (if then entitled to appoint a director hereunder) or by the holders of at least seventy-five percent (75%) of the combined voting power of the Preferred Stock (if General Atlantic is not then entitled
to appoint a director hereunder); and Section 2(a)(v) and the applicable clause of Section 2(d) shall not be amended or 

  
 - 11 - 

 
waived without the written consent of EW Healthcare (if then entitled to appoint a director hereunder) or by the holders of at least seventy-five percent (75%) of the combined voting power of the
Preferred Stock (if EW Healthcare is not then entitled to appoint a director hereunder); provided, further, that any waiver or amendment of Section 4(c)(iv), Section 4(d), this
Section 9 and any other provision in this Agreement relating to rights specific to holders of the Series E Preferred Stock shall not be amended or waived without the written consent of the holders of at least sixty-five
percent (65%) of the voting power of the Series E Preferred Stock; provided, further, that any amendment or waiver of this Agreement in a manner that adversely affects the rights of the Stockholders shall also require the written
consent of the holders of a majority of the combined voting power of Shares held by the Stockholders; provided, further, that any amendment or waiver of this Agreement in a manner that adversely affects the rights of the holders of any
series of Preferred Stock in a manner that is different than other similarly situated series of Preferred Stock shall also require the written consent of the holders of a majority of the voting power of such adversely affected series of Preferred
Stock; provided, however, that any amendment or waiver of this Agreement in a manner that adversely affects any Investor in a manner different from any other Investor shall require the written consent of the adversely affected
Investor. Any amendment or waiver effected in accordance with this Section 9 shall be binding upon the Company, the Voting Parties, and each of their respective successors and assigns. Notwithstanding the foregoing,
Exhibits A and B hereto may be amended by the Company without the consent of the other parties hereto from time to time to reflect (i) additional Stockholders pursuant to Section 7(b); or (ii) in
connection with transfers of Shares held by Investors permitted pursuant to the terms of Section 10. 
 10.
Transfers. Each transferee or assignee of any Shares subject to this Agreement shall continue to be subject to the terms hereof, and, as a condition precedent to the Company’s recognizing such transfer, each transferee or assignee shall
agree in writing to be subject to each of the terms of this Agreement by executing and delivering a Joinder Agreement substantially in the form attached hereto as Exhibit C. Upon the execution and delivery of a Joinder Agreement by any
transferee, such transferee shall be deemed to be a party hereto as if such transferee were the transferor and such transferee’s signature appeared on the signature pages of this Agreement and shall be deemed to be an Investor and Voting Party,
or Stockholder and Voting Party, as applicable. The Company shall not permit the transfer of the Shares subject to this Agreement on its books or issue a new certificate representing any such Shares unless and until such transferee shall have
complied with the terms of this Section 10. Each certificate representing the Shares subject to this Agreement if issued on or after the date of this Agreement shall be endorsed by the Company with the legend set forth in
Section 6. 
 11. Notices. Any notice required or permitted by this Agreement shall be in writing and shall
be deemed sufficient on the date of delivery, when delivered personally or by overnight courier or sent by telegram or fax, or forty-eight (48) hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid,
and addressed to the party to be notified at such party’s address as set forth on the signature pages hereto, or as subsequently modified by written notice. 

12. Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to
renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be excluded from this Agreement, (b) the balance of
this Agreement shall be interpreted as if such provision were so excluded; and (c) the balance of this Agreement shall be enforceable in accordance with its terms. 

  
 - 12 - 

 13. Governing Law. THE LAWS OF THE STATE OF DELAWARE SHALL GOVERN THE VALIDITY AND
INTERPRETATION OF THIS AGREEMENT AND THE PERFORMANCE BY THE PARTIES HERETO OF THEIR RESPECTIVE DUTIES AND OBLIGATIONS HEREUNDER. 
 14.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 

15. Successors and Assigns; Entire Agreement. This Agreement, the Purchase Agreement, the Transaction Agreements (as defined in the
Purchase Agreement), the Restated Certificate and the exhibits hereto constitute the entire contract between the Company and the Voting Parties relative to the subject matter hereof. Subject to the exceptions specifically set forth in this
Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective executors, administrators, heirs, successors and assigns of the parties. Nothing in this Agreement, express or implied, is
intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Upon
the execution and delivery of this Agreement by the requisite Investors and the Company, the Prior Voting Agreement shall thereafter be of no further force and effect and is hereby amended and restated herein. 

[Signature pages follow] 

  
 - 13 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first written above. 
  

			
	COMPANY:	  	ADDRESS:
		
	SONENDO, INC.	  	26051 Merit Circle, Suite 102 
Laguna Hills, CA 92653

  

			
		
	By:	 	/s/ Bjarne Bergheim
		 	Bjarne Bergheim,
		 	President and Chief Executive Officer

  

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

					
	STOCKHOLDER AND INVESTOR:	 		 	ADDRESS:
			
	/s/ Bjarne Bergheim	 		 	  

	    Bjarne Bergheim	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

					
	STOCKHOLDER:	 		 	ADDRESS:
			
		 		 	26051 Merit Circle, Suite 102 
Laguna Hills, CA 92653
			
	/s/ Olav B. Bergheim	 		 	  

	    Olav B. Bergheim	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

			
	INVESTOR:	  	ADDRESS:
		
	CVF, LLC	  	 222 N. La Salle Street
 Suite 200 
Chicago,
IL 60601

  

			
		
	By: By:	 	/s/ Richard H. Robb

			
	Name:	 	Richard H. Robb
	Title:	 	Manager

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

			
	INVESTOR:	  	ADDRESS:
		
	EW Healthcare Partners Fund 2, L.P.	  	21 Waterway Avenue, Suite 225 
The Woodlands, TX 77380

  

			
		
	By:	 	/s/ Martin P. Sutter

			
	Name:	 	Martin P. Sutter
	Title:	 	Managing Director

  

			
	EW Healthcare Partners Fund 2-A, L.P.	  	 21 Waterway Avenue, Suite 225 
The Woodlands, TX 77380

  

			
		
	By:	 	/s/ Martin P. Sutter
	Name:	 	Martin P. Sutter
	Title:	 	Managing Director

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

			
	INVESTOR:	  	ADDRESS:
		
	FJORD CAPITAL PARTNERS I, L.P.	  	 26051 Merit Circle, Suite 102
 Laguna Hills, CA
92653

		  	

  

			
		
	By:	 	Fjord Venture Partners I, LLC
		
	Its:	 	General Partner
		
	By:	 	/s/ Olav B. Bergheim
		 	Olav B. Bergheim,
		 	Manager

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

			
	STOCKHOLDER AND INVESTOR:	  	ADDRESS:
		
	FJORD VENTURES LLC	  	26051 Merit Circle, Suite 102 
Laguna Hills, CA 92653

  

			
		
	By:	 	/s/ Olav B. Bergheim
		 	Olav B. Bergheim,
		 	President

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

							
	INVESTOR:	 		 	ADDRESS:
			
	 FJORDINVEST, LLC,
 a Nevada limited
liability company
	 		 	 c/o Becker Financial
 2082 Michelson Drive,
Suite 302
 Irvine, CA 92612

	By:	 	/s/ Olav B. Bergheim	 		 	
		 	 Olav B. Bergheim,
 Manager
	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

							
	INVESTOR:	 		 	ADDRESS:
			
	 FJORDINVEST (CAYMAN) LTD.
	 		 	 26051 Merit Circle, Suite 102
 Laguna Hills, CA
92653

	By:	 	/s/ Olav B. Bergheim	 		 	

							
	Name:	 	Olav B. Bergheim,	 		 	
	Its:	 	Chief Executive Officer	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

							
	INVESTOR:	 		 	ADDRESS:
			
	 FJORDINVEST (CAYMAN) II LTD.
	 		 	 26051 Merit Circle, Suite 102 
Laguna Hills, CA 92653

	By:	 	/s/ Olav B. Bergheim	 		 	

							
	Name:	 	Olav B. Bergheim,	 		 	
	Its:	 	Chief Executive Officer	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

					
	INVESTOR:	 		 	ADDRESS:
			
	GAMLA LIVFÖRSÄKRINGSAKTIEBOLAGET SEB TRYGG LIV (publ)	 		 	106 40 Stockholm
Sweden

  

			
		
	By:	 	/s/ Anders Jöngard
	Name:	 	Anders Jöngard
	Title:	 	Inv Director

  

			
		
	By:	 	/s/ Victor Lang
	Name:	 	Victor Lang
	Title:	 	CIO, SEB PE

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

					
	INVESTOR:	 		 	ADDRESS:
			
	 GENERAL ATLANTIC (SOI), L.P.
  

By: General Atlantic (SPV) GP, LLC, its general partner
	 		 	 c/o General Atlantic Service Company, LLC
 55
East 52nd Street, 32nd Floor
 New York, NY 10055

			
	By: General Atlantic, LLC its sole member	 		 	
			
	 By: /s/ J. Frank Brown                

Name: J. Frank Brown
 Title: Managing Director
	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

					
	INVESTOR:	 		 	ADDRESS:
			
	 JMR CAPITAL LIMITED
	 		 	  
 c/o Kitano Capital

2711 N. Haskell Avenue
 Suite 1650

	 By: /s/ David
Nishida                        

David Nishida, Director
	 		 	Dallas, TX 75204

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

					
	INVESTOR:	 		 	ADDRESS:
			
	 Meridian Small Cap Growth Fund
 By: its
Investment Adviser
 ArrowMark Colorado Holdings, LLC
	 		 	 10 Fillmore Street, Suite 325
 Denver, CO
80206

			
	 By: /s/ David
Corkins                        

Name: David Corkins
 Title: Managing Member
	 		 	
			
	 ArrowMark Life Science Fund, LP
 By: its
General Partner
 AMP Life Science GP, LLC
	 		 	
			
	 By: /s/ David
Corkins                          

Name: David Corkins
 Title: Managing Member
	 		 	
			
	 ArrowMark Fundamental Opportunity Fund, L.P.

By: its General Partner
 ArrowMark Partners GP, LLC
	 		 	
			
	 By: /s/ David
Corkins                          

Name: David Corkins
 Title: Managing Member
	 		 	
			
	Lookfar Investments, LLC	 		 	
			
	 By: /s/ David
Corkins                          

Name: David Corkins
 Title: Managing Member
	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

					
	 INVESTOR:
	 		 	 ADDRESS:

			
	MERITECH CAPITAL AFFILIATES IV, L.P.	 		 	 245 Lytton Avenue, Suite 125
 Palo Alto, CA
94301

			
	 By: Meritech Capital Associates IV L.L.C.,
 its
General Partner
	 		 	

  

			
	By:	 	/s/ Paul Madera
		 	Paul Madera, a managing member

			
	
	MERITECH CAPITAL PARTNERS IV, L.P.
	
	By: Meritech Capital Associates IV L.L.C., its General Partner

			
		
	By:	 	/s/ Paul Madera
		 	 Paul Madera, a managing member

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

					
	 INVESTOR:
	 		 	 ADDRESS:

			
	 MICRO, LLC 
	 		 	 c/o Becker Financial
 2082 Michelson Drive,
Suite 302
 Irvine, CA 92612

  

			
	By:	 	/s/ Olav B. Bergheim
		 	 Olav B. Bergheim
 Its: Manager

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting Agreement as of
the date first above written. 
  

			
	 INVESTOR:
	  	 ADDRESS:

		
	 N5 INVESTMENTS AS 
	  	 Parkveien 55

N-0256 Oslo

Norway

  

			
	By:	 	/s/ Pal R.
Jensen                                        

		 	 Name: Pal R. Jensen

Its:   CEO

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

			
	 INVESTOR:
	  	 ADDRESS:

		
	 NEOMED INNOVATION V L.P.
  

By: Its General Partner, NeoMed Innovation V Limited
	  	 13 Castle Street
 St. Helier

Jersey
 JE4 5UT

  

			
	By:	 	/s/ Ashley Vardon
		 	 Name: Ashley Vardon
 Title:
Director

		
	By:	 	/s/ Christina Kembery
		 	 Name: Christina Kembery
 Title:
Director

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

					
	STOCKHOLDER AND INVESTOR:	 		 	ADDRESS:
			
	/s/ Hugh Andrew Neuharth	 		 	  

	Hugh Andrew Neuharth	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

													
	INVESTOR:	 		 	 ADDRESS:

			
	ORBIMED PRIVATE INVESTMENTS IV, LP	 		 	OrbiMed Private Investments IV, LP
		 		 		 		 		 	OrbiMed Advisors, LLC
	 By:
	 	OrbiMed Capital GP IV LLC,	 		 		 	601 Lexington Avenue, 54th Floor
		 	its General Partner	 		 		 	New York, NY 10022
						
		 	 By:
	 	OrbiMed Advisors LLC,	 		 		 	
		 		 	its Managing Member	 		 		 	

													
							
		 		 	By:	 	/s/ Carl Gordon	 		 		 	

													
		 		 	 Name: Carl Gordon
 Title: Member

	 		 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

									
	INVESTOR:	 		 	ADDRESS:
			
	 PENSCO Trust Company, Custodian
	 		 	
	 FBO Olav Bergheim IRA.
	 		 	

									
					
	By:	 	/s/ Chris Rains	 		 		 	

									
	Name:	 	Chris Rains	 		 		 	

									
	 Its:
	 	Authorized Signatory	 		 		 	

									
					
	By:	 	/s/ Olav Bergheim	 		 		 	

									
	Name:	 	Olav Bergheim	 		 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

							
	INVESTOR:	 		 	ADDRESS:
			
	PERCEPTIVE LIFE SCIENCES MASTER FUND	 		 	 51 Astor Place, 10th Floor

New York, New York 10003
 Attn: Steve
Berger

							
				
	By:	 	/s/ James H. Mannix	 		 	  

							
	Name:	 	James H. Mannix	 		 	
	Title:	 	C.O.O.	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

			
	INVESTOR:	  	ADDRESS:
		
	SECURITY PACIFIC FINANCE, LTD.	  	 c/o RBC Trustees (Guernsey) Ltd.
 P.O. Box 48
Canada Court
 GYI 38Q St. Peter Port
 Guernsey, Channel
Islands

  

			
		
	By:	 	/s/ Tanya Marrett /s/ Martyn Russell

			
	Name:	 	Tanya Marrett and Martyn Russell
	TItle:	 	Authorized Signatories for RBC
	Directorship Services (Guernsey) Limited Director

			
		
	By:	 	/s/ Tanya Marrett /s/ Martyn Russell

			
	Name:	 	Tanya Marrett and Martyn Russell
	TItle:	 	Authorized Signatories for RBC
	Corporate Services (Guernsey) Limited Director

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

					
	INVESTOR:	 		 	ADDRESS:
			
	/s/ Andrew Wade	 		 	  

	Andrew Wade	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

			
	INVESTOR:	  	ADDRESS:
		
	BROADFIN HEALTHCARE MASTER FUND LTD	  	 300 Park Ave
25th Floor

New York, NY 10022

			
		
	By:	 	/s/ Kevin Ketter

			
	Name:	 	Kevin Ketter
	Title:	 	Director

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated Voting
Agreement as of the date first above written. 
  

							
	INVESTOR:	 		 	ADDRESS:
			
	Redmile Private Investments II, L.P.	 		 	c/o Redmile Group, LLC
		 		 	One Letterman Drive
		 		 	Suite D3-300
	By:	 	/s/ Josh Garcia	 		 	San Francisco, CA 94129

							
	Name:	 	Josh Garcia	 		 	
	Title:	 	 Chief Financial Officer and Authorized

Signatory of Redmile Group, LLC, the
 managing member of Redmile
Private
 Investments II (GP), LLC, its general partner
	 		 	

  
 [Signature Page to Fifth
Amended and Restated Voting Agreement of Sonendo, Inc.] 

 EXHIBIT A 

SCHEDULE OF STOCKHOLDERS 
 Bjarne Bergheim

 Olav Bergheim 
 Thomas R. Engels 

Fjord Ventures LLC 
 Morteza Gharib 

Erik Hars 
 Hugh Neuharth 

 EXHIBIT B 

SCHEDULE OF INVESTORS 
 ArrowMark
Fundamental Opportunity Fund, LP 
 ArrowMark Life Science Fund, LP 

Bjarne Bergheim 
 Troy Bremer 

Broadfin Healthcare Master Fund, Ltd. 
 Thomas R. Engels 

Daniel and Phyllis Even, Joint Tenants 
 EW Healthcare Partners
Fund 2, L.P. 
 EW Healthcare Partners Fund 2-A, L.P. 

Fjord Capital Partners I, LP 
 Fjord Ventures, LLC 

Fjordinvest, LLC 
 Fjordinvest (Cayman) Ltd. 

The Stuart and Marianne Foster Trust 
 Kieran and Mary Ellen
Gallahue Family Trust 
 Gamla Livförsäkringsaktiebolaget Seb Trygg Liv (publ) 

The Huennekens Family Trust dtd 6/14/2007 
 James R. Margolis and
Marja P. Margolis JTWROS 
 Lookfar Investments, LLC 
 Meridian
Small Cap Growth Fund 
 Meritech Capital Affiliates IV, L.P. 

Meritech Capital Partners IV, L.P. 
 Micro, LLC 

Gary S. Mocnik Retirement Trust 
 N5 Investments AS 

NeoMed Innovation V L.P.     
 Hugh Neuharth

 Orbimed Private Investments IV, LP 
 Redmile Private
Investments, II, L.P. 
 The Board Of Trustees Of The Leland Stanford Junior University (SBST) 

TIP-Sonendo Limited 
 Andrew Wade 

DNA 07 Limited 
 Timwell Corporation Limited 

CVF, LLC 
 Fjordinvest (Cayman) II Ltd. 

JMR Capital Limited 
 Per Magnus Andersson 

Security Pacific Finance, Ltd. 
 Randy W. Garland, DDS, Inc. Cash
Balance Plan &Trust 
 Reid V. Pullen, D.D.S., P.C. 

 Chad O. Edwards 

Marcus Palermo 
 Pirooz A. Zia 

General Atlantic (SOI), L.P. 
 Perceptive Life Sciences Master
Fund 
 CPV Holdings, LLC 
 PENSCO Trust Company, Custodian FBO
Olav Bergheim IRA. 

 EXHIBIT C 

Joinder Agreement to Sonendo, Inc. 

Fifth Amended and Restated Voting Agreement 

The undersigned hereby agrees, effective as of the date hereof, to become a party to, and be bound by and subject to the terms of, that
certain Fifth Amended and Restated Voting Agreement (the “Agreement”) dated as of December 10, 2019, as may be amended from time to time, by and among Sonendo, Inc. (the “Company”) and the other parties from
time to time named therein, and for all purposes of the Agreement, the undersigned shall be included within the term Stockholder as a Stockholder thereunder, as defined in the Agreement. The address and facsimile number to which notices shall be
sent to the undersigned are as follows: 
 Address: 
  

			
	By:
	
	 
	Print Name:
	
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]